Esketamine at a Clinical Dose Attenuates Cerebral Ischemia/Reperfusion Injury by Inhibiting AKT Signaling Pathway to Facilitate Microglia M2 Polarization and Autophagy Article Swipe
Related Concepts
Autophagy
Microglia
PI3K/AKT/mTOR pathway
Protein kinase B
Medicine
Pharmacology
Ischemia
Signal transduction
Neuroscience
Chemistry
Inflammation
Cell biology
Biology
Immunology
Internal medicine
Apoptosis
Biochemistry
Ying Gao
,
Lu Li
,
Fang Zhao
,
Yi Cheng
,
Mu Jin
,
Fu‐Shan Xue
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.2147/dddt.s504179
· OA: W4406598766
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.2147/dddt.s504179
· OA: W4406598766
Esketamine at a clinical dose attenuates cerebral I/R injury by inhibiting AKT signaling pathway to facilitate microglial M2 polarization and autophagy. Furthermore, esketamine combined autophagy inducer can provide an improved protection against cerebral I/R injury. Thus, this study provides new insights into the neuroprotective mechanisms of esketamine and the potential therapeutic strategies of cerebral I/R injury.
Related Topics
Finding more related topics…